The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer

BACKGROUND: Previously, it was demonstrated that serum levels of tumor markers, CEA and CA19-9, correlated with chemotherapy. Consequently, it has been hypothesized that dynamic monitoring of changes in these markers may predict the shrinkage or growth of colorectal cancers. To test this hypothesis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Jun, Zhang, Pengfei, Gou, Miaomiao, Yang, Fan, Qian, Niansong, Dai, Guanghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360556/
https://www.ncbi.nlm.nih.gov/pubmed/30805037
http://dx.doi.org/10.1155/2019/6812045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360556/
https://www.ncbi.nlm.nih.gov/pubmed/30805037
http://dx.doi.org/10.1155/2019/6812045

Ejemplares similares